Диссертация (1155060), страница 19
Текст из файла (страница 19)
– V. 1P.1003-10.69.Chen, R.Y. Duration of highly active antiretroviral therapy regimens/ R.Y.Chen, A.O. Westfall, M.J. Mugavero et al / Clin Infect Dis. - 2003.- V.37(5).P.714-722.70.Clinical management and treatment of HIV-infected adults in Europe, EACSGuidelines - Version 5–4, March, 2011 [Электронный ресурс] Режимдоступа:http:www.europeanaidsclinicalsociety.org(датаобращения: 14.10.2017).71.daCostaDiBonaventura M.
The association of HIV/AIDS treatment sideeffects with health status, work productivity, and resource use/ M.daCostaDiBonaventura, S.Gupta, M. Cho, J. Mrus // AIDS Care. -2012.V.24(6). - P.744-55.72.d'ArminioMonforte A. Insights into the reasons for discontinuation of the firsthighly active antiretroviral therapy (HAART) regimen in a cohort of118antiretroviral naïve patients ICONA Study Group Italian Cohort ofAntiretroviral-Naïve Patients / A. d'ArminioMonforte, A.C. Lepri, G.
Rezzaet al / AIDS. – 2000 .– V. 14(5). – P.499-507.73.Davidson, I., Beardsell, H., Smith, B., et al The frequency and reasons forantiretroviral switching with specific antiretroviral associations: the SWITCHstudy // Antiviral Res. – 2010.–V.86(2)– P.227-9.74.De Cock K.M. The public health implications of AIDS research in Africa./K.M. De Cock, E. Ekpini, E. Gnaore, A.
Kadio, H.D. Gayle// JAMA. - 1994.272(6): Р. 481–486.75.Dixon, S. The impact of HIV and AIDS on Africa’s economic development/S. Dixon, S. McDonald, J. Roberts // BMJ. – 2002. - 324(7331):Р.232–234.76.Drechsler, H. Switching effective antiretroviral therapy: a review/ H.Drechsler, W.G. Powderly// Clin Infect Dis. – 2002. – V.15;35(10). – Р.12193.77.Elzi, L. Swiss HIV Cohort Study. Treatment modification in humanimmunodeficiencyvirus-infectedindividualsstartingcombinationantiretroviral therapy between 2005 and 2008 / L. Elzi, C.
Marzolini, H. Furreret al // Arch Intern Med. - 2010 V.170(1). – P.57-65.78.Ford, K. Migrant seafarers and HIV risk in Thai communities/ K. Ford, A.Chamratrithirong //. AIDS Educ Prev. – 2008. - 20(5):- Р.454–463.79.Gebo, K.A. Contemporary costs of HIV healthcare in the HAART era / K.A.Gebo, J.A. Fleishman, R. Conviser et al // AIDS. – 2010.- V. 13.- P.27052715.80.Ghatnekar, O. Medical resource utilization and cost of 51. HIV-related care inthe highly active antiretroviral therapy era at a University Clinic in Sweden./O. Ghatnekar, C. Hjortsberg, M. Gisslén, M// Pharmacoeconomics. – 2010.
–V.28 .- P.49-57.81.Guidelines for the use of antiretroviral agents in HIV-1-infected adults andadolescents. Developed by the panel on clinical practices for treatment of HIVinfection convened by the Department of Health and Human Services119(DHHS). 10 January 2011. [Электронный ресурс]. - Режим доступа: http:https://aidsinfo.nih.gov/contentfiles/PediatricGuidelines003005.pdf(датаобращения 12.12.2016).82.Ha, B. Virologic response and safety of the abacavir/ lamivudine fixed-doseformulation as part of highly active antiretroviral therapy: analyses of sixclinical studies / B.
Ha, Q.M. Liao, L.P. Dix, K.A. Pappa//HIV Clin. Trials. 2009.- 10(2): Р65–75.83.Hakim, A.J. The Epidemiology of HIV and Prevention Needs of Men WhoHave Sex with Men in Abidjan, Cote d'Ivoire/ A.J. Hakim, J. Aho, G. Semde,M. Diarrassouba, K. Ehoussou, B. Vuylsteke, C.S. Murrill, M. Thiam,T.Wingate // PLoS One. 2015 Apr 24;10(4):e0125218.P.1-13.84.Hart, E.
National review of first treatment change after starting highly activeantiretroviral therapy in antiretroviral-naïve patients / E. Hart, H. Curtis, E.Wilkins // HIV Med. – 2007 .–V.8(3).–P.186-91.85.Hecht, R., Alban, A., Taylor, K., Post, S., Andersen, N.B., Schwarz, R. Puttingit together: AIDS and the millennium development goals. PLoS Med. – 2006.- 3(11):e455.86.Hellinger, F. J. The lifetime cost of treating a person with HIV.
JAMA 1993Jul 28;270(4):478-8.87.Hetherington, S.Understanding drug hypersensitivity: what to look for whenprescribing abacavir. AIDS Read. – 2001. - Dec;11(12): Р.620-2.88.Hetherington, S. Hypersensitivity reactions during therapy with the nucleosidereverse transcriptase inhibitor abacavir/ S. Hetherington, S. McGuirk, G.Powell et al.//Clin Ther.
– 2001.-23: Р.1603–1614.89.Hill, A. Optimizing HIV treatment /A. Hill // CurrOpin HIV AIDS. – 2013. V 8 (1). – P.34-40.90.Hill, A. Dose optimisation: a strategy to improve tolerability and lowerantiretroviral drug prices in low and middle income countries/ A. Hill, J.Ananworanich, A. Calmy// Open Infect Dis J 2010; 4:P.85–91.12091.Hogg, R. Antiretroviral Therapy Cohort Collaboration. Life expectancy ofindividuals on combination antiretroviral therapy in high-income countries: acollaborative analysis of 14 cohort studies / R. Hogg, V. Lima, J.A.
Sterne //Lancet. –2008. –V. 26.– P. 293-299.92.Holt, B.Y., Effler, P., Brady, W., et al. Planning STI/HIV prevention amongrefugees and mobile populations: situation assessment of Sudanese refugees.Disasters. – 2003. - 27(1):1–15.93.How Health Systems Can Address Health Inequities Linked to Migration andEthnicity.[Электронный ресурс]. Copenhagen: WHO Regional Office forEurope,2010.-Режимдоступа:http://www.euro.who.int/__data/assets/pdf_file/0007/129868/e94606.pdf(дата обращения :15.02.2017).94.Hurt, C.B. Transmitted antiretroviral drug resistance among acute and recentHIV infections in North Carolina from 1998 to 2007 / C.B.
Hurt // AntivirTher.- 2009. –V.14(5). P.673–678.95.Johnson, A.A. Toxicity of antiviral nucleoside analogs and the humanmitochondrial DNA polymerase/ A.A. Johnson, A.S. Ray, J. Hanes et al. //. JBiol Chem. - 2001.- 276: 40845–40857.96.Jos, C.M. Mossink, M.Sc., M.I.M. Understanding and Performing EconomicAssessments at the Company Level [Электронный ресурс].
Geneva. WHO –2002. - Режим доступа: http://apps.who.int/iris/bitstream/10665/42491/1/WHO_SDE_OEH_01.9.pdf (дата обращения: 21.10.2016).97.Kallings, L.O. The first postmdern pandemic: 25 years of HIV/ AIDS. //JInternMed. – 2008.–V.263.–P.218-243.98.Karkee, R., Shrestha, D.B. HIV and conflict in Nepal: relation and strategy forresponse. Kathmandu Univ Med J (KUMJ). – 2006. - 4(3):363–367.99.Kiguba, R. Discontinuation and modification of highly active antiretroviraltherapy in HIV-infected Ugandans: prevalence and associated factors / R.Kiguba, J. Byakika-Tusiime, C. Karamagi // J Acquir Immune DeficSyndr. 2007.-V.45(2).- P.218-23.121100.Kumarasamy, N. Reasons for modification of generic highly activeantiretroviral therapeutic regimens among patients in southern India / N.Kumarasamy, S.
Vallabhaneni, A.J. Cecelia// J Acquir Immune DeficSyndr. –2006.– V. 41(1) – P.53-58.101.Kuritzkes, D.R. Drug resistance in HIV-1 // Curr OpinVirol. – 2011 .–V.1(6).P.582–589.102.Lenzi, L., Wiens, A., Pontarolo, R. Evaluation of adverse events associatedwith antiretroviral therapy and the relationship to treatment adherence.// Int JClinPharmacolTher.– 2013.– V.51(2):141-6.103.Levy, A. The impact of disease stage on direct medical costs of HIVmanagement: a review of the international literature/ A. Levy, K.
Johnston, L.Annemans et al // Pharmacoeconomics. – 2010. V. 28.- P. 35-47.104.Levy, A.R. The direct costs of HIV/AIDS care/ A.R. Levy, D. James, K.M.Johnston et al // Lancet Infect Dis. – 2006. – V.6(3). – P.171-177.105.Levy, J.A. 25 Years of AIDS: recording progress and future changelles/ J.A.Levy, R.A.
Coutinho // AIDS.-2012.-V.26(10).-P.1187-1189.106.Long, L. The high cost of second-line antiretroviral therapy for HIV/AIDS inSouth Africa/ L. Long, M. Fox, I. Sanne // AIDS. – 2010. – V. 27.- P.915-919.107.Mallal, S., Nolan, D., Witt, C., Masel, G., Martin, A.M., Moore, C., et al.Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet.– 2002.
- 359(9308):727–732.108.Mallal, S., Phillips, E, Carosi, G., et al. HLA-B*5701 screening forhypersensitivity to abacavir. N Engl J Med 2008, 358:568-79.109.Max, B., Sherer, R. Management of the adverse effects of antiretroviraltherapy and medication adherence / B. Max, R. Sherer //Clin Infect Dis.–2000.–V.28.- P.34-46.110.Merito, M. Economic evaluation of HIV treatments: the ICONA cohort study/ M. Merito, A. Bonaccorsi, F.
Pammolli // Health Policy. - 2005.- V.74(3).P.304-313.122111.Messou, E. Antiretroviral treatment changes in adults from Côte d'Ivoire: theroles of tuberculosis and pregnancy / E. Messou, X. Anglaret, J. Duvignac etal // AIDS. – 2010. - V.24(1) - P.93-99.112.Meyer-Rath, G. Cost and resource use of patients on antiretroviral therapy inthe urban and semiurban public sectors of South Africa/ G. Meyer-Rath, A.Miners, A.C. Santos et al . / J Acquir Immune DeficSyndr. - 201-2. V. 61(3).– P.25-32.113.Migueles, S.A., et al. HLA B*5701 is highly associated with restriction ofvirusreplication in a subgroup of HIV-infected long term nonprogressors.ProcNatl AcadSci USA97(6):2709–2714. -2000.114.Mocroft, A., Lundgren, J.D., Sabin, M.L., Monforte, Ad.A., Brockmeyer, N.,Casabona, J., Castagna, A., Costagliola, D., Dabis, F., De wit S et al: RiskFactors And Outcomes For Late Presentation For Hiv-Positive Persons InEurope:ResultsFromTheCollaborationOfObservationalHivEpidemiological Research Europe Study (Cohere).
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
